Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximab
Our results support that intrathecal inflammatory activity is still ongoing in patients with NTZ and RTX. Cross-sectional GFAP might indicate a lower risk for long-term disability in the RTX group. Our data should be interpreted with caution because of small sample size, making it difficult to control for multiple confounders.
Authors
- Magnus Förnvik Jonsson (ORCID: https://orcid.org/0000-0002-9227-744X)
- Anders Svenningsson (ORCID: https://orcid.org/0000-0003-0663-2220)
- Maria Strandberg (ORCID: https://orcid.org/0000-0001-8349-2044)
- Oskar Hansson (ORCID: https://orcid.org/0000-0001-8467-7286)
- Shorena Janelidze (ORCID: https://orcid.org/0000-0003-2869-8378)
- Kristina Källén (ORCID: https://orcid.org/0000-0001-6601-2256)
- Johan Hellgren (ORCID: https://orcid.org/0009-0002-1491-2003)
- Isabella Ahlström
Institutions
- Lund University (SE)
- Danderyds sjukhus (SE)
- Karolinska Institutet (SE)
- Helsingborgs lasarett (SE)
- Skåne University Hospital (SE)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.msard.2025.106479
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00